CAMBRIDGE, Mass., July 24, 2008 (PRIME NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Bruce A. Leicher, J.D. has been appointed as the Company’s Senior Vice President and General Counsel.
Craig A. Wheeler, CEO of Momenta, commented, “Bruce brings nearly 20 years of legal experience in the biotechnology industry to Momenta, and we are very pleased to have him join our executive team. In particular, his expertise with the management of a broad range of complex biotechnology legal matters, including intellectual property litigation, adds invaluable expertise to our organization as we advance our pipeline of generic and novel compounds.”
Prior to joining Momenta, Mr. Leicher was Senior Vice President and General Counsel at Altus Pharmaceuticals. He previously served as General Counsel at Antigenics Inc., as Vice President and Chief Pharmaceutical Counsel for Millennium Pharmaceuticals, Inc. and as Vice President, Legal for Genetics Institute, Inc. Mr. Leicher received his J.D. from Georgetown University Law Center and his B.A. from the University of Rochester.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company’s most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta’s first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company’s discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars’ functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley 617-395-5189 Yates Public Relations Media: Barbara Yates 781-258-6153
Comments